Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

6.440 +0.320 (+5.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Analyst Expectations for Vir Biotechnology's Future ↗

January 27, 2023

Via Benzinga

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

January 25, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

2 Stocks That Could Turn $100 Into $1,000 by 2028 ↗

January 22, 2023

These growth stocks have substantial tailwinds.

Via The Motley Fool

Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A

December 21, 2022

– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –

From Vir Biotechnology, Inc.

Via GlobeNewswire

2 Fast-Growing Healthcare Stocks to Buy and Hold ↗

December 02, 2022

The innovative companies have made great gains in a short period of time.

Via The Motley Fool

BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗

December 02, 2022

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...

Via Benzinga

European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗

November 25, 2022

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...

Via Benzinga

After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade ↗

November 18, 2022

Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.

Via Benzinga

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

November 16, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action ↗

November 07, 2022

Via Benzinga

Why Vir Biotechnology Jumped Nearly 19% Today ↗

November 04, 2022

A COVID-19 partnership with a major drugmaker is producing more fruit than expected.

Via The Motley Fool

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting ↗

November 15, 2022

Via Benzinga

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection

November 06, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 04, 2022

Gainers

Via Benzinga

Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates ↗

October 04, 2022

Via Benzinga

Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday ↗

November 07, 2022

Gainers

Via Benzinga

Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session ↗

November 04, 2022

Gainers

Via Benzinga

What 5 Analyst Ratings Have To Say About Vir Biotechnology ↗

November 04, 2022

Over the past 3 months, 5 analysts have published their opinion on Vir Biotechnology (NASDAQ:VIR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth ↗

November 04, 2022

Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates.

Via Investor's Business Daily

Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday ↗

November 04, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 03, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2022 ↗

November 03, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Via Benzinga

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022

October 31, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022

October 28, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny ↗

October 20, 2022

Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to...

Via Benzinga

This Addiction Drug Shows Some Potential Against Long COVID Symptoms ↗

October 19, 2022

Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection.

Via Benzinga

Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A

October 18, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

October 11, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

All News about Vir Biotechnology, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today